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Abstract 
Introduction 
The number of children with autism spectrum disorder (ASD) is rising, along with the potential for 
challenging behaviors during health care encounters. 
Method 
We present an overview of the emerging science related to ASD diagnosis and interventions for 
children with ASD. 
Results 
Emerging science on ASD reveals common associated challenging behaviors, increasing prevalence, 
emphasis on early diagnosis at 18 to 24 months of age, changes in the diagnostic process with criteria 
from the Diagnostic and Statistical Manual of Mental Disorders, 5th edition, and interventions with 
medication, education, and behavior management. 
Discussion 
Family and health care provider preparation strategies facilitate care of children with ASD and their 
families. Early diagnosis at 18 to 24 months of age and evidence-based interventions contribute to best 
outcomes for children and families. Health care providers must be aware of the state of the science for 
diagnosis and best practices to provide family-centered care for this growing population. 
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Autism spectrum disorder (ASD) is a developmental disorder that presents with atypical language and 
social behavior, along with restrictive and repetitive behaviors and unusual interests (American 
Psychiatric Association [APA], 2013). The spectrum of behaviors and their severity are highly variable 
(Hall, 2012). The behaviors may be self-inflicted (e.g., hitting or biting oneself) and/or externalized 
(e.g., hitting or kicking others; Johnson, Bekhet, Robinson, & Rodriguez, 2014; Matson et al., 2011). 
Behaviors may be exacerbated when children are stressed, such as in health care settings (Hall, 2012, 
Johnson and Rodriguez, 2013, Johnson et al., 2014, Matson et al., 2011). 
Discerning the most accurate information about ASD to use as a basis for recommendations for family-
centered ASD treatment can be challenging for nurse practitioners and other health care practitioners 
(HCPs), given the complexity of the symptoms and wide range of presentation (Lounds Taylor et al., 
2012, Warren et al., 2011). The objective of this review article is to describe the evidence for the HCP's 
role in screening, the diagnostic process, and interventions with children who have ASD. We present 
background on the current state of the science related to ASD definition, associated behaviors, 
prevalence, the diagnostic process, and interventions. 
ASD Definition 
The definition of ASD has developed over time since it was introduced in the third edition of the 
Diagnostic and Statistical Manual of Mental Disorders (DSM-III; American Psychiatric Association [APA], 
1980). Prior to 1980, ASD symptoms were considered to be representative of early onset schizophrenia 
(American Psychiatric Association, 1952, American Psychiatric Association, 1968). The fourth revision of 
the DSM categorized the symptoms of ASD into three distinct pervasive developmental disorders 
(PDDs): autism, PPD–not otherwise specified, and Asperger syndrome (APA, 1994). The classification of 
the PDDs did not change with the DSM IV–text revision (APA, 2000). With the fifth edition of the DSM, 
the three PDDs are collapsed into one diagnostic disorder, ASD. The diagnosis of Asperger syndrome 
and PDD–not otherwise specified are no longer given in the DSM-5. Future prevalence studies may be 
affected, given the change in the categorization of ASD with the DSM-5 (Swineford, Thurm, Baird, 
Wetherby, & Swedo, 2014). 
The new DSM-5 diagnostic disorder ASD has two main criteria: (A) persistent social communication 
and social interaction deficits and (B) restricted, repetitive patterns of behavior, interests, or activities 
(see Box 1). A child may demonstrate all of the A criteria as early as age 2 years if the child does not 
respond to his or her name, has no or limited joint attention, and shows a lack of reciprocal interaction. 
An example of the B criteria in a toddler is an unusually strong interest in a play telephone during 
which time he does not engage with his mother, respond to his name, or share enjoyment with his 
mother about the phone. Adherence to restricted routines can lead to difficulties with transitions and 
challenging behaviors, such as tantrums (Weitlauf et al., 2014). 
Box 1 
Criteria for diagnosis of autism spectrum disordera 
Criteria A: Persistent social communication and social interaction deficits in multiple contexts. 
Includes deficits in all three areas: 
• Social-emotional reciprocity. 
• Nonverbal communicative behaviors used for social interaction. 
• Developing, maintaining, and understanding relationships. 
Criteria B: Restricted, repetitive patterns of behavior, interests, or activities. Includes at least 
two: 
• Stereotyped or repetitive movements, use of objects, or speech. 
• Insistence on sameness, inflexible adherence to routines, or ritualized patterns of verbal 
or nonverbal behavior. 
• Highly restricted, fixated interests that are abnormal in intensity or focus. 
• Hyper- or hyporeactivity to sensory input or unusual sensory environment interest. 
Criteria C: Symptoms were present in early developmental period. 
Criteria D: Symptoms correlate with clinically significant impairments in social or occupational 
functioning. 
Criteria E: Impairments are not better explained by intellectual disability or global 
developmental delay. 
Clinician specifies the following: 
• With or without intellectual impairment. 
• With or without language impairment. 
• Any associated or known medical or genetic condition. 
• Any associated neurodevelopmental, mental or behavioral disorder. 
Severity rating: 
Level 1: Requires support. 
Level 2: Requires substantial support. 
Level 3: Requires very substantial support. 
 
Note. aAdapted criteria for Autism Spectrum Disorder in the Diagnostic and Statistical Manual 
for Mental Disorders, edition 5 (American Psychiatric Association, 2013). 
 
The DSM-5 also requires clinicians to specify other diagnoses that may be present, such as cognitive or 
language impairment, known medical or genetic conditions, and other neurodevelopmental or 
behavior disorders (APA, 2013). The clinician rates the severity of the ASD on three levels. Level 1 
requires support; level 2 requires substantial support; and level 3 requires very substantial support 
(APA, 2013). 
Associated Behaviors 
Challenging behaviors that accompany ASD are sometimes very difficult for families to manage. A 
variety of behaviors are associated with ASD. For example, aggression and self-injury have a significant 
impact on quality of life for children and families on the autism spectrum (Johnson, Frenn, Feetham, & 
Simpson, 2011). Anxiety is often seen to be a trigger for these behaviors (Davis et al., 2011). The 
anxiety can be linked to both receptive and expressive communication skill deficits that accompany 
ASD (Davis et al., 2010). Children with ASD also may have obsessive-compulsive features or the need 
for predictability and sameness. These characteristics can lead to some stressful situations for families 
(Miles, 2011). 
Prevalence of ASD 
Based on DSM-IV criteria, the prevalence of ASD in the United States is estimated to have increased 
from 1 in 10,000 people in the 1990s (Rutter, 2007) to 1 in 68 people (about 4.7 million) in 2014, with a 
4:1 male to female prevalence (Baio et al., 2014). The broadening of the concept of autism in the DSM-
IV to include Asperger syndrome increased the supports for ASD and the diagnostic surveillance in 
health and educational care. It also improved ASD awareness, which helps explain the increasing ASD 
prevalence (Baio et al., 2014, Fombonne, 2009, Rutter, 2007). 
Some of the symptoms of ASD are subtle and therefore difficult to recognize on a consistent 
basis, which complicates the HCP's ability to recognize the earliest signs of ASD. 
Some of the symptoms of ASD are subtle and therefore difficult to recognize on a consistent basis, 
which complicates the HCP's ability to recognize the earliest signs of ASD. This subtlety can add 
another layer of diagnostic uncertainty for the clinician working with the culturally diverse child. 
Although the ASD phenotype (i.e., how the child looks and behaves) does not differ by culture, the 
prevalence of ASD among diverse cultural groups differs significantly. White children have a 30% 
greater prevalence for being diagnosed with ASD than African American children and a 50% greater 
prevalence than Hispanic children (Baio et al., 2014). 
African American and Hispanic children are diagnosed with ASD on average 2.5 to 2.6 years later than 
White children (Kerfeld et al., 2011, Mandell et al., 2002, Mandell et al., 2009, Valicenti-McDermott 
et al., 2012). When African American and Hispanic children are diagnosed later, their ASD symptoms 
can be more severe, including poorer social reciprocity or the risk for an intellectual disability (Baio 
et al., 2014, Jarquin et al., 2011). Additionally, African American children with ASD are more often 
misdiagnosed with a behavioral disorder such as attention deficit hyperactivity disorder, adjustment 
disorder, or conduct disorder than are White children (Mandell, Ittenbach, Levy, & Pinto-Martin, 2007). 
Lags in obtaining the ASD diagnoses for African American and Hispanic children can lead to preventable 
delays in implementing interventions to improve outcomes (Burkett, Morris, Manning-Courtney, 
Anthony, & Shambley-Ebron, 2015). These preventable delays represent a health care disparity in the 
United States. Multiple cultural factors contribute to lack of early diagnosis and lack of timely 
interventions for African American and Hispanic children with ASD, including (a) HCP diagnostic bias of 
the White male child, whose prevalence of diagnosis with ASD is typically higher than that of other 
ethnicities; (b) poorer health care accessibility than White children; (c) uncertainties about the 
presenting symptoms of African American and Hispanic children; and (d) family understanding of ASD 
symptoms (Mandell et al., 2007). When HCPs offer diagnostic and intervention care to families of 
culturally diverse backgrounds based on knowledge and understanding of these cultural factors, there 
exists a greater potential for reducing the gap of health care disparities for African American and 
Hispanic children with ASD (Burkett and Morris, 2015, Zuckerman et al., 2014). 
The Diagnostic Process 
Early Identification of ASD 
Identification of ASD as early as 18 to 24 months of age is imperative so HCPs can direct families of 
children with ASD to evidence-based treatments for the best child and family outcomes (Weitlauf 
et al., 2014). Multiple studies have shown the effectiveness of early and intensive treatments on child 
outcomes in ASD (Dawson et al., 2010, Weitlauf et al., 2014). In response to this urgent need to 
recognize the signs of ASD early in a child's life, the Centers for Disease Control and Prevention (CDC) 
developed the “Learn the Signs Act Early” campaign, including a booklet listing normal child 
developmental milestones (Daniel, Prue, Taylor, Thomas, & Scales, 2009). An element of the campaign 
is the development and distribution of “Milestones booklets” that list the normal child developmental 
milestones. These booklets are available as a free download on the CDC Web site 
(http://www.cdc.gov/ncbddd/actearly/freematerials.html). To date, no research studies are available 
in the medical literature with regard to the effectiveness of this campaign. 
The CDC also provides training video clips of the key early indicators of a risk for ASD to assist clinicians 
in the diagnostic process. The Learn the Signs Act Early Curriculum: Autism Case Training Videos 
(http://www.cdc.gov/NCBDDD/video/actearlycurriculum/index.html) are illustrative and promote 
understanding of the qualitative impairments of ASD, supplemented by the written text definitive 
criteria for ASD as outlined in the DSM-5 manual. 
Primary care screening 
Primary care providers screen for ASDs for children 18 and 24 months of age based on American 
Academy of Pediatrics (AAP) guidelines (Council on Children With Disabilities, 2006, Johnson and 
Myers, 2007). Numerous screening tools specific to ASD symptoms are available (Council on Children 
With Disabilities, 2006, Gardner, 2012, Zwaigenbaum, 2011). A commonly used tool is the Modified 
Checklist for Autism in Toddlers Revised Form (Herlihy et al., 2014, Robins et al., 2014). Primary care 
providers refer children for expert diagnostic evaluations if they appear to be at risk for ASD, based on 
this preliminary screening tool. Box 2 lists absolute “red flags” that should prompt referral for further 
diagnostic evaluation for ASD. These red flags are generally accepted by developmental specialists and 
are consistent with the social communication and restricted and repetitive behavior hallmarks of ASD. 
For children with positive ASD screening results and clinician concern, timely referral to both a 
developmental clinic for further diagnostic evaluations and referral to community early intervention 
program should occur simultaneously (Gardner, 2012, Johnson and Myers, 2007, Manning-Courtney 
et al., 2013). 
Box 2 
Absolute indications for referral for autism spectrum disorder diagnostic evaluation 
No babbling by 12 months 
No gesturing (e.g., pointing and waving bye-bye) by 12 months 
No single words by 16 months 
No two-word spontaneous (not echolalic) phrases by 24 months 
Any loss of any language or social skills at any age 
Note. Data from Filipek et al., 2000, Gardner, 2012, Johnson and Myers, 2007. 
 
Expert Diagnosis 
No medical or diagnostic markers exist to definitively diagnose ASD. The diagnostic process by experts 
involves comprehensive developmental screening by a multidisciplinary team of clinicians, including 
ASD-specific screening, which has been shown to be more reliable in detecting ASD than clinician 
observation alone (Daniels and Mandell, 2013, Guevara et al., 2013, Miller et al., 2011). The team 
evaluation consists of a developmental pediatric evaluation, administration of an ASD-specific 
diagnostic instrument, and a psychological evaluation. The developmental pediatric evaluation includes 
a detailed family, birth, medical, and developmental history, physical and neurologic examination, and 
developmental observations. The ASD-specific diagnostic instrument is the Autism Diagnostic 
Observation Schedule (ADOS), which is a standardized instrument that assesses social and 
communicative functions (Lord et al., 2012). Trained evaluators from any discipline such as speech and 
language, psychology, nursing, and education can administer the ADOS. The ASD-specific psychology 
evaluation includes standardized cognitive (intelligence quotient [IQ]), behavioral, emotional, and ASD-
specific assessments. 
Further medical evaluations are customized to the individual clinical situation. Because one early 
indicator of ASD is the inability of a child to orient to his or her name (Schaefer & Mendelsohn, 2013), 
all children should have an audiogram to rule out hearing loss as part of the effort to secure an 
accurate diagnosis. Children with significant hearing loss may display socialization and communication 
difficulties and be misidentified as having ASD (Schaefer & Mendelsohn, 2013). After an accurate 
diagnosis, the primary care medical home provider should refer the child for genetics evaluation 
because ASD is thought to have a genetic basis (Schaefer & Mendelsohn, 2013). 
Genetic and Genomics of Autism 
The underlying cause of ASD and the subsequent challenging behaviors of children with ASD is the 
subject of much debate and research. It is commonly accepted that ASD is influenced by genetics 
(Buxbaum et al., 2014, Johnson et al., 2013b; Myers et al., 2011, Veenstra-Vanderweele et al., 2004), 
contributing factors in the environment (Shelton, Hertz-Picciotto, & Pessah, 2012), and maternal 
immune-mediated responses (Lyall, Ashwood, Van de Water, & Hertz-Picciotto, 2014). Researchers are 
studying several environmental factors that may affect gene expression and that also may modify gene 
expression via epigenetic changes (Shulha et al., 2012). 
An international consortium of researchers has progressed in our understanding of ASD genetics by the 
use of candidate gene analysis, gene sequencing, and the study of copy number variants 
(CNVs; Buxbaum et al., 2014). Current research supports a major genetic contribution in children 
diagnosed with ASD in approximately 10% of children assessed by Fragile X testing and chromosome 
microarray analysis (Buxbaum et al., 2014). Fragile X, a single gene disorder affecting intellectual 
ability, is the most common single known cause of ASD (Kidd et al., 2014). Chromosome microarray 
analysis is a test that detects deletion or duplications of stretches of deoxyribonucleic acid known as 
CNVs. Chromosome microarray analysis is increasingly recommended in autism spectrum disorders 
(Peters & Pertile, 2014). Ongoing research seeks to determine new genetic biomarkers that measure 
the causes of ASD with more accuracy. 
With the heterogeneity of ASD, it is difficult to tell how the genetic determinants affect socialization 
and behavior directly. Various models attempt to understand the connection of the ASD genotype to 
the phenotype. One model depicts ASD as a disturbance of physiological and behavioral rhythms that 
possibly affect the child's development of social communication impairments and repetitive behaviors 
and interests (Tordjman et al., 2015). For now, HCPs assess and treat the symptoms of the co-morbid 
conditions rather than treating ASD as a singular disorder. The identification of an underlying genetic 
disorder would help provide a unifying diagnosis for the child with ASD (Schaefer & Mendelsohn, 
2013). Many syndromes have an established documented association with ASD (Johnson et al., 2013b, 
Schaefer and Mendelsohn, 2013; see Table 1). For these syndromes, no further investigation of the 
cause of the ASD is needed (Schaefer & Mendelsohn, 2013). There is no known cure for ASDs or 
consensus regarding the most effective intervention strategy (Myers & Johnson, 2007). Evidence 
suggests that only a minority of children progress to the point where they do not meet ASD diagnostic 
criteria (Fein et al., 2013). 
Table 1. Genetic disorders associated with autism spectrum disorder 
Disorder Incidence % Co-occurring 
with ASD 
Descriptions 
Fragile X 1/3,600 
males; 
15-30 (Harris, 
2011) 
Single gene disorder affecting intellectual 
ability (Harris, 2011) 
1/8,000 
females 
Rett syndrome 1/10,000 
females 
25-40 (Harris, 
2011) 
Regressive neurodevelopmental disorder of 
speech and unusual hand movement (Neul 
et al., 2010) 
Tuberous sclerosis 1/6,000 25-60 (Harris, 
2011) 
Nonmalignant tumors primarily in the brain, 
eyes, and heart 
Down syndrome 1/691 40 (Warner, 
Moss, Smith, & 
Howlin, 2014) 
Low muscle tone, small stature; more 
behavior problems than children with Down 
syndrome only (Warner, Moss, Smith, & 
Howlin, 2014) 
Note. ASD = autism spectrum disorder. 
Data from Siegel & Beaulieu, 2012. 
 
Interventions 
Two systematic reviews of therapies for persons with ASD have been performed—one for children up 
to 12 years old (Weitlauf et al., 2014) and one for children ages 12 to 18 years (Lounds Taylor et al., 
2012). Both reviews address areas for medical, educational, and behavioral interventions that may be 
used as evidence for clinical guidelines. In the review for the children aged 12 to 18 years, only five 
studies on medications were available, most of which were poor quality, pointing to a need for more 
research for this age group (Lounds Taylor et al., 2012). 
Families typically choose which interventions to use for their child (Karst & Van Hecke, 2012) but tend 
to not have the time, resources, or expertise to consider all the options available (Stephenson, Carter, 
& Kemp, 2012). The high cost and variability in public funding and insurance coverage for some ASD 
interventions and complicated step-by-step formats of some interventions limit their feasibility and 
accessibility. As a result, parents may choose diets or medications not proven to be effective simply 
because they are straightforward interventions available at home (Lord & Bishop, 2010). Matson, 
Adams, Williams, and Rieske (2013) report that there is low parental adherence and compliance to 
medically prescribed treatments. In addition, parents may experience high levels of stress as a result of 
the child's challenging behaviors. This stress takes a toll on the health of parents and may lead them to 
delay seeking care for their child (Bekhet et al., 2012, Cantwell et al., 2014, Johnson et al., 2011, 
Kerfeld et al., 2011, Lovell et al., 2012). 
Recent literature highlights the importance of collaboration between parents and HCPs, known as 
shared decision making (SDM), for treatment selection, rather than simply expecting parent and child 
adherence to treatment recommendations (Institute of Medicine, 2015, Strauss et al., 2015, U.S. 
Department of Health and Human Services, 2010). Caregivers of children with ASD report a lack of 
SDM, difficulty accessing services, poor care coordination, and adverse family experiences compared 
with caregivers of children with developmental disabilities, mental health conditions, or both (Carbone 
et al., 2010, Vohra et al., 2014). Two inherent issues exist: limited SDM for ASD, and, even when SDM is 
present, a lack of HCPs who understand the complexity of parenting a child with ASD (Bultas, 2012, 
Johnson et al., 2011). 
Medical and Related Interventions 
Medical interventions target the symptoms of the developmental, psychiatric, neurologic, and 
gastrointestinal disorders that may co-occur with ASD (Levy et al., 2010). After receiving the medical 
diagnosis of ASD, children may be referred to specialists or an ASD center for ongoing developmental 
and medical follow up of co-occurring conditions. The focus in follow-up medical visits can often be 
problem-focused, reviewing with the family their day-to-day care of their child with ASD. As with many 
other chronic medical conditions, other medical problems can be seen that require acute episodic 
health care. 
Seizures 
Approximately 30% of children on the autism spectrum may have seizures sometime during their life 
(Tuchman, Moshe, & Rapin, 2009). Andell and colleagues (2015) reported that the most common 
neurodevelopment comorbidities of children 0 to 18 years (n = 766) who had a new-onset unprovoked 
seizure were developmental delay (22%; confidence interval [CI], 19% to 25%), speech/language and 
learning difficulties (23%; CI, 20% to 26%), and intellectual disability (16%; CI, 13% to 18%). Seizures 
were more common in older children with co-occurring psychiatric diagnosis (Andell et al., 2015). The 
onset of epilepsy peaks during adolescence and adulthood in ASD, for unknown reasons, and may be 
unique to children with ASD compared with other developmental disabilities (Tuchman et al., 2009). 
Gastrointestinal disturbances 
Research on specific gastrointestinal disorders that co-occur with ASD is limited. Gastrointestinal 
symptoms are difficult to evaluate because of the child's limited communication (Buie et al., 2010). 
Problem behavior in children with ASD may be the primary or sole symptom of an underlying 
gastrointestinal condition (Buie et al., 2010). Parents report that gastrointestinal issues are often the 
antecedent to challenging child behaviors and dysregulated sleep (Coury, Ashwood, et al., 2012). These 
conditions include gastroesophageal reflux disease, eosinophilic esophagitis, or and/or constipation 
(Coury, Ashwood, et al., 2012). Sensory integration differences may result in textural aversions to 
certain foods and a limited repertoire of food choices with a very selective diet (Badalyan and 
Schwartz, 2012, Chandler et al., 2013). The altered eating habits, along with psychopharmacological 
treatment, genetics, disordered sleep, and lack of adequate physical activity, contribute to the risk of 
obesity in this population (Curtin, Jojic, & Bandini, 2014). Children with ASD have a higher prevalence 
of obesity than the general population (Curtin, Anderson, Must, & Bandini, 2010). 
Some parents of children with ASD try the gluten casein-free diet in an attempt to help improve their 
child's behavior. The diet is an exclusion diet that is costly and inconvenient. Evidence is lacking that 
following this diet improves a child's challenging behaviors and cognitive and social functioning 
(Millward, Ferriter, Calver, & Connell-Jones, 2008). Furthermore, following a gluten casein-free diet 
may place children at risk for suboptimal bone development (Geraghty, Depasquale, & Lane, 2010). 
Pain sensitivity 
In a systematic review of the pain of children with ASD, children with ASD were found to have different 
patterns of pain and discomfort expression than typically developing children. Instead of crying and 
seeking comfort, some children with ASD express pain differently (Allely, 2013). For example, some 
children with ASD who are in pain display the following: “furrowed brow,” “banging his/her head,” 
“injuring oneself,” “grimacing,” “guarding,” and “increased heart rate” (Inglese, 2008). Other identified 
indicators of pain may be subjective and required (a) knowledge of the child's baseline and (b) 
monitoring for changes from normal (i.e., “crankiness,” “being less active,” “rocking unusually,” 
“acting,” “off,” and “irritability”; Inglese, 2008). HCPs must be careful to not interpret this lack of 
typical finding as pain insensitivity or incorrectly assume that the child is in no pain (Allely, 2013). Close 
collaboration with parents to learn how their child expresses pain is indicated because some parents 
are able to describe unique behaviors that let them know when their child is in pain (Allely, 2013). 
Medication Management of Symptoms of ASD 
The use of medication in children with ASD is varied and usually symptom-specific. No medication has 
yet been developed that targets the core deficits seen in ASD—specifically, disordered language and 
social skill deficits. However, when concurrent medical symptoms are present, medications can be 
useful. The use of medication is carefully reviewed in the context of current health status and ongoing 
treatments. In determining a medication for behavior concerns, a careful history is needed to identify 
what may be triggering symptoms. For example, if anxiety seems to precede behavior outbursts, then 
anti-anxiety medication may be appropriate. The HCP should review with the family that the goal of 
medication treatment is to lessen the intensity of a symptom that may be interfering with the child's 
ability to make progress. Deciding to begin a medication is often a “try and see” or trial approach, with 
a “start low and go slow” format for making dose adjustments (Reinhold & Manning-Courney, 2007). 
Many children with ASD take psychotropic medications for challenging behaviors. In one study, Coury 
and colleagues determined the percentage of children with ASD (n = 2,853 children ages 3 to 17 years) 
who took at least one psychotropic medication by age range as follows: 11% of children aged 3 to 
5 years; 46% of children aged 6 to 11 years; and 66% of children aged 12 to 17 years (Coury, 
Anagnostou, et al., 2012). Thus more teenagers are medicated than are children. The number of 
clinical trials of psychotropic medications continues to increase, which is helpful in guiding clinical 
practice. Measuring outcomes in the use of these medications continues to be difficult. Additionally, 
many medications in current use are considered “off-label,” without Food and Drug Administration 
(FDA) approval. However, avoiding agents that are off-label limits choices for potentially efficacious 
treatment. Currently, only two psychotropic medications, risperidone and aripiprazole, have FDA 
approval in the treatment of children with aggression and ASD (Weitlauf et al., 2014). Overall, 
medication combined with behavioral intervention appears to be more effective for reducing 
aggressive behavior than medication alone (Dawson & Burner, 2011). 
Many children with ASD take psychotropic medications for challenging behaviors. 
Some children on the autism spectrum have significant inattention, distractibility, and/or hyperactive 
behavior. Stimulant medications such as methylphenidate (Ritalin) diminish impulsivity and 
hyperactivity by blocking the reuptake of catecholamine (norepinephrine and dopamine) at the 
synaptic cleft (Purper-Ouakil, Ramoz, Lepagnol-Bestel, Gorwood, & Simonneau, 2011). Stimulants 
improve focus and decrease aggression for children with and without ADHD (Blader et al., 2013). 
Table 2 lists common problems and psychotropic medications used in the treatment of ASD. 
Table 2. Co-occurring conditions, diagnostics, and medications for autism spectrum disorder 
Problem Comments Medications 
Anxiety and 
obsessive 
compulsive 
features 
Medications are not the first line of 
treatment but may be helpful in 
lowering anxiety 
SSRI medications have not been 
studied enough to know if they are 
helpful for ASD symptoms 
SSRIs carry a black box warning 
Benzodiazepines are used with 
caution because of the possibility of 
paradoxical effect and/or tolerance 
SSRIs: citalopram, clomipramine, 
desipramine, fluoxetine, fluvoxamine, 
paroxetine, and sertraline; 
An alternate anxiolytic, buspirone, has 
been used as an add-on medication or 
an alternative to the SSRI category 
Hyperactivity, 
distractibility, 
or inattention 
Stimulant medications have not 
been studied enough to know if they 
are helpful for ASD symptoms 
Atomoxetine cannot be crushed or 
sprinkled and takes several weeks 
for onset 
Alpha 2 agonists (short and long 
acting) have been used off label and 
in younger children 
Stimulant: methylphenidate 
Amphetamine and 
dextroamphetamine: Adderall 
Alpha-2 agonist: clonidine, guanfacine 
Aggression, 
agitation, self-
injurious behavior 
Only two medications approved for 
the treatment of agitation and 
aggression in children with ASD: 
risperidone and aripiprazole 
Antipsychotics associated with 
weight gain, sleepiness, tremors and 
abnormal movements 
Antiepileptic medications have been 
used to stabilize mood 
Antipsychotic agents: aripiprazole 
chlorpromazine, clozapine, haloperidol, 
olanzapine, perphenazine, risperidone, 
and ziprasidone 
Mood stabilizer: carbamazepine, 
divalproex, lamotrigine, levetiracetam, 
lithium, and oxcarbazepine 
Seizures 1. EEG studies recommended for 
staring with unresponsiveness 
2. Neuroimaging studies 
recommended if EEG abnormalities 
are present 
Antiepileptic medications: lamotrigine, 
oxcarbazepine, valproate 
Note. ASD = autism spectrum disorder; EEG = electroencephalogram; SSRI = selective serotonin 
reuptake inhibitor. 
Data from Siegel & Beaulieu, 2012. 
 
Educational Intervention 
The Individuals with Disabilities Education Improvement Act (IDEIA) mandates that parents of children 
aged 3 to 21 years with ASD be actively involved in decisions about the services and accommodations 
for their child through SDM (U.S. Department of Education, 2015). According to IDEIA, state 
departments of instruction are mandated to identify students with ASD and provide services in special 
education programs in the local school district for those older than 3 years. For children younger than 
3 years, early intervention services are available throughout the United States, based in state county 
programs (U.S. Department of Education, 2015). Some children may only be diagnosed with ASD as 
part of a school evaluation rather than a formal evaluation for ASD. An educational diagnosis of ASD is 
based on the criteria from IDEIA (IDEIA, 2004). This educational ASD diagnosis can be quite helpful in 
guiding the child's individualized educational plan. 
Early intervention services must be provided in natural environments, including the home and 
community settings in which children without disabilities participate. 
Early intervention services must be provided in natural environments, including the home and 
community settings in which children without disabilities participate. Parents of children with ASD are 
supported to help their children generalize skills learned at school into the home (Carter et al., 2013, 
Machalicek et al., 2008). Children receive other therapeutic interventions at school, such as speech and 
language therapy and occupational therapy for fine motor deficit and sensory integration difficulties 
(Weitlauf et al., 2014). 
Behavioral Interventions 
Numerous interventions have been designed to target the core features of ASD—that is, social 
communication and social interaction deficits and restricted, repetitive patterns of behavior, interests, 
or activities (see Table 3). Applied behavior analysis (ABA) is considered a best practice for the 
education of children with ASD, intellectual disability, and related disorders (Hagopian & Hardesty, 
2015). ABA was first defined in 1968 as the process of systematically applying interventions based 
upon the principles of learning theory directed at improving the behavior (Baer, Wolf, & Risley, 1968). 
Table 3. Select interventions for autism spectrum disorder 
Program Select examples Focus 
Early intensive 
behavioral 
intervention 
1. Applied behavior analysis (Lovaas, 1987) Overall development 
 
2. Early Start Denver (Dawson et al., 2010) Overall development, 
core symptoms, adaptive 
behavior  
3. Pivotal response training (Koegel, Koegel, 
Harrower, & Carter, 1999) 
Parent led, play based 
 
4. Floor time therapy derived from the 
Developmental Individual-Difference 
Relationship–based model (Wieder & Greenspan, 
2003) 
Parent follows child's 
lead 
Cognitive 
behavioral therapy 
1. Coping Cat (McNally Keehn, Lincoln, Brown, & 
Chavira, 2013) 
Helps high-functioning 
children manage anxiety  
2. Facing your fears (Reaven, Blakeley-Smith, 
Leuthe, Moody, & Hepburn, 2012) 
Helps high-functioning 
children manage anxiety 
Social skills 
programs 
1. Skill streaming (Goldstein & McGinnis, 1997) Social skills, attention, 
play 
 
2. Joint attention, symbolic play, engagement, and 
regulation (JASPER; Kasari, Gulsrud, Paparella, 
Hellemann, & Berry, 2015) 
Parent mediated for joint 
attention and 
cooperative play 
 
ABA uses a behaviorist approach for either comprehensive or focused interventions (Hagopian & 
Hardesty, 2015). Comprehensive interventions aim to improve skills that have an impact on global 
measures of functioning over time, such as IQ, language/communication, socialization, discrimination, 
and attention (Hagopian & Hardesty, 2015). Small amounts of information are presented in repeated 
trials, using clear interactions, which are structured in a three-part contingency pattern (antecedent-
response-consequence; Weitlauf et al., 2014). Comprehensive ABA is generally home based for 25 to 
40 hours/week for several years (Hagopian & Hardesty, 2015). By contrast, focused interventions occur 
over a shorter amount of time. For example, a functional behavioral assessment to identify the 
variables antecedent to a problem behavior, such as aggression or self-injury, is considered a focused 
intervention (Hagopian & Hardesty, 2015). 
Scientific support during the past 40 years links ABA-based procedures with reduction of problem 
behaviors and increasing appropriate skills (Hagopian & Hardesty, 2015). Research on children who 
received comprehensive ABA therapy for at least 8 months to 2 years showed greater improvements in 
cognitive performance, language skills, and adaptive behavior skills than broadly defined eclectic 
treatments available in the community (Weitlauf et al., 2014). A subset of all children who receive early 
intensive intervention showed significant improvement in terms of standardized outcomes, although 
many children continue to have substantial problems (Weitlauf et al., 2014). Research also shows 
promise for Naturalistic Developmental Behavioral Interventions (Schreibman et al., 2015), which use 
the principles of ABA in settings that are naturalistic, such as home and with a different arrangement of 
the three-part contingency. For example, a child may be placed in an environment (e.g., the kitchen) 
where he or she has to initiate an interaction with someone (e.g., ask for an apple) to get a desired 
item (apple) (Schreibman et al., 2015). 
Some evidence suggests that improvements with ABA may vary with the underlying severity of the 
disorder, but more research for the correlates of improvement is needed (Weitlauf et al., 2014). Future 
research needs to look at how family functioning affects outcomes of ABA therapy and include 
measures of parental well-being (Howlin, Magiati, & Charman, 2009). Because family functioning 
affects child behaviors, all children who receive ABA therapy may not have acquired adequate adaptive 
behavior skills to cope with stressful acute episodic health care interactions. In an effort to help with 
family functioning, Autism Speaks has created tool kits with evidence-based guidance for parents with 
children with challenging behaviors (Autism Speaks, 2012) and ABA therapy (Autism Speaks, 2015). 
More information on the behavior management of children with ASD can be found in part 2 of this 
two-part publication on translating evidence to practice for children with ASD. 
Conclusion 
The research base representing the translation of evidence to practice for the health care of children 
with ASD is still a developing area of research. We presented background on the current state of the 
science related to ASD definition, associated behaviors, prevalence, diagnostic process, and 
interventions. This evidence can inform health care institution clinical guidelines and policies. Future 
research is needed to test interventions that decrease children's challenging behaviors and promote 
SDM among HCPs and families to optimize child and family health outcomes in health care settings. 
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